Continuous Improvement & Updates Flashcards

A regulatory affairs team is implementing Key Performance Indicators (KPIs) for continuous improvement. Which KPI directly measures the quality of regulatory submissions?

Answer: Rate of Information Requests (IR) or Major Objections received per submission

The rate of Information Requests or Major Objections received indicates submission quality—high IR rates suggest deficiencies in content, format, or data package completeness.

An FDA inspector observes during a PAI that a company's CAPA system contains 47 open CAPAs, many overdue by more than a year. This finding MOST likely indicates:

Answer: The CAPA system lacks adequate resources, timelines, and management oversight to ensure effective closure

Large numbers of overdue CAPAs are a classic indicator of a CAPA system that identifies problems but lacks the management commitment, resources, and tracking to resolve them effectively.

ICH Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management) introduced the concept of Established Conditions (ECs). How do ECs support continuous improvement?

Answer: ECs distinguish between changes requiring regulatory submissions and those that can be managed internally, streamlining innovation

ICH Q12 ECs define the minimum set of conditions requiring regulatory notification, allowing manufacturers to make non-EC changes internally and enabling faster implementation of improvements.

A company receives a Form 483 observation stating that its product failure investigations do not extend to other batches that may be affected. Under 21 CFR 211.192, the corrective action must ensure that:

Answer: Investigations consider the potential impact on other batches manufactured using the same equipment, materials, or process

21 CFR 211.192 requires that failure investigations extend to other batches that could be affected by the same root cause to protect patients from potentially compromised product.

During a continuous improvement review, a team finds that post-market change supplements consistently take longer to prepare than industry benchmarks. The MOST effective process improvement would be to:

Answer: Implement a change impact classification system and pre-approved templates for common change types

A classification system with pre-approved templates for common change types reduces rework, ensures completeness, and allows regulatory staff to focus effort on novel complex changes.

A medical device company's post-market surveillance (PMS) data reveals a statistically significant increase in a specific user error. Under EU MDR Article 83, the company's PSUR must:

Answer: Include the trend data, benefit-risk analysis, and any corrective actions taken to address the user error pattern

EU MDR PSURs must include post-market surveillance data findings—including use-error trends—along with benefit-risk reassessment and any actions taken.

A pharmaceutical company uses a statistical process control (SPC) chart and detects a run of 8 consecutive points on the same side of the mean for a critical process parameter. This pattern indicates:

Answer: A special-cause signal suggesting a systematic shift that requires investigation

Eight consecutive points on the same side of the mean is a classic Western Electric Rule indicating a non-random systematic shift, which is a special-cause signal requiring root cause investigation.